Date: Tuesday, March 19, 2024
Time: 10:00 am – 11:00 am PT / 1:00 pm – 2:00 pm ET
Speakers: Kristine Ashcraft, Victoria Pratt, Glenn Sawyer
Sponsored by Agena Bioscience®Register Now
Precision medicine and pharmacogenomics (PGx) have become increasingly critical components of healthcare, but a lack of standardization in clinical laboratory processes and reporting has, up to this point, hindered widespread adoption and implementation.
In this panel discussion, PGx experts Vicky Pratt, past president of AMP and director of scientific affairs for pharmacogenetics at Agena, and Kristine Ashcraft, founder of YouScript, will discuss the current state of PGx standardization and how they see things taking shape for the future by addressing such topics as:
Kristine Ashcraft, BS, MBA
President and Founder, YouScript
Kristine Ashcraft has worked in pharmacogenomics since 2000 and was named one of the 25 leading global voices in precision medicine. She is the founder and president of YouScript, a clinical decision support tool that has integrated PGx-guided personalized prescribing in the clinical workflow for over a decade. Ashcraft has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing and serves on numerous PGx advisory groups including the STRIPE Steering Committee, the FDA collaborative community for pharmacogenomics, CPIC, and the American Cancer Society Cancer Action Network PGx task force.
Victoria M. Pratt, Ph.D., FACMG
Director, Scientific Affairs for Pharmacogenetics, Agena Bioscience
Victoria Pratt is the past president of the Association for Molecular Pathology. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM program for reference materials for molecular genetics, the National Academy of Medicine’s Roundtable on Genomics and Precision Health, and the American Medical Association’s Molecular Pathology Current Procedural Terminology Advisory committee. Pratt graduated with a doctorate in medical and molecular genetics from Indiana University School of Medicine. Her fellowship training was in medical and clinical molecular genetics at Henry Ford Hospital in Detroit.
Glenn Sawyer, MBA
Associate Director, Clinical Genetics, Agena Bioscience
Glenn Sawyer is the associate director of clinical genetics for Agena Bioscience. With over 25 years in the biotech space, he has broad knowledge in the scientific and technical arena as well as commercial strategy and execution. Sawyer has held roles that encompass assay design and development, molecular laboratory R&D, field applications, field sales, sales training, product management, and marketing. Prior to joining Agena Bioscience, Sawyer was a senior market manager at Hologic, in field applications and field sales with Roche Diagnostics, and in R&D and marketing with Gen-Probe. He holds a patent for a quantitative HIV molecular diagnostic assay and has successfully launched commercial molecular instrumentation and assays throughout his career.